BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10587291)

  • 1. Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma.
    Corona G; Aita P; Sorio R; Colussi AM; Bearz A; Sartor F; Boiocchi M; Toffoli G
    Anticancer Drugs; 1999 Oct; 10(9):815-9. PubMed ID: 10587291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
    Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
    Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
    Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
    Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetic aspects of oral administration of etoposide].
    Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
    Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma.
    Cheng AL; Chen YC; Yeh KH; Chuang SE; Chen BR; Chen DS
    Cancer; 1996 Mar; 77(5):872-7. PubMed ID: 8608477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
    Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
    Raschko JW; Synold TW; Chow W; Coluzzi P; Hamasaki V; Leong LA; Margolin KA; Morgan RJ; Shibata SI; Somlo G; Tetef ML; Yen Y; ter Veer A; Doroshow JH
    Cancer Chemother Pharmacol; 2000; 46(5):403-10. PubMed ID: 11127945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).
    McClay EF; Bogart J; Herndon JE; Watson D; Evans L; Seagren SL; Green MR;
    Am J Clin Oncol; 2005 Feb; 28(1):81-90. PubMed ID: 15685040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
    Edick MJ; Gajjar A; Mahmoud HH; van de Poll ME; Harrison PL; Panetta JC; Rivera GK; Ribeiro RC; Sandlund JT; Boyett JM; Pui CH; Relling MV
    J Clin Oncol; 2003 Apr; 21(7):1340-6. PubMed ID: 12663724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
    Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN
    Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
    Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
    Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide.
    Sato H; Kitazawa H; Adachi I; Horikoshi I
    Pharm Res; 1996 Oct; 13(10):1565-9. PubMed ID: 8899852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
    Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
    Cancer Chemother Pharmacol; 1995; 37(1-2):161-7. PubMed ID: 7497587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic optimisation of treatment with oral etoposide.
    Toffoli G; Corona G; Basso B; Boiocchi M
    Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children.
    Eksborg S; Söderhäll S; Frostvik-Stolt M; Lindberg A; Liliemark E
    Anticancer Drugs; 2000 Apr; 11(4):237-41. PubMed ID: 10898537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.
    Mross K; Bewermeier P; Reifke J; Krüger W; Stockschläder M; Zander A; Hossfeld DK
    Bone Marrow Transplant; 1994 Apr; 13(4):423-30. PubMed ID: 8019466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
    Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of grapefruit juice intake on etoposide bioavailability.
    Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL
    Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.